Actoxumab is a recombinant monoclonal antibody specifically designed to neutralize Clostridium difficile toxin A (TcdA). By binding to TcdA, Actoxumab effectively prevents the toxin's deleterious effects on the intestinal wall and mitigates the associated inflammatory responses. This antibody is particularly noted for its synergistic action when used in conjunction with Bezlotoxumab, which targets Clostridium difficile toxin B (TcdB). Together, these antibodies provide a comprehensive approach to managing the effects of both major C. difficile toxins. Actoxumab is valuable in research focused on the pathogenesis and treatment of C. difficile infections.
Actoxumab is a recombinant monoclonal antibody specifically designed to neutralize Clostridium difficile toxin A (TcdA). By binding to TcdA, Actoxumab effectively prevents the toxin's deleterious effects on the intestinal wall and mitigates the associated inflammatory responses. This antibody is particularly noted for its synergistic action when used in conjunction with Bezlotoxumab, which targets Clostridium difficile toxin B (TcdB). Together, these antibodies provide a comprehensive approach to managing the effects of both major C. difficile toxins. Actoxumab is valuable in research focused on the pathogenesis and treatment of C. difficile infections.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
